Back to top
more

Merck KGaA (MKGAF)

(Delayed Data from OTC)

$153.78 USD

153.78
36

-2.23 (-1.43%)

Updated Apr 22, 2024 10:59 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

HEXO (HEXO) delivered earnings and revenue surprises of -900% and 15.51%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 30.77% and 11.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -29.55% and 23.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?

by Zacks Equity Research

Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bears are Losing Control Over Merck KGaA (MKGAF), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

John Blank headshot

Consumer Price Inflation Really Matters

by John Blank

What CPI index groups should you consult?

The Zacks Analyst Blog Highlights Banco Do Brasil, Merck KGaA and Ecopetrol

by Zacks Equity Research

Banco Do Brasil, Merck KGaA and Ecopetrol are included in this Analyst Blog.

John Blank headshot

Big Banks Show Q3 Earnings: Global Week Ahead

by John Blank

U.S. inflation numbers, retail sales data, consumer sentiment gauges and minutes from the Federal Reserve's latest meeting will give market watchers plenty to chew on.

John Blank headshot

Big Banks Show Q3 Earnings: Global Week Ahead

by John Blank

U.S. inflation numbers, retail sales data, consumer sentiment gauges and minutes from the Federal Reserve's latest meeting will give market watchers plenty to chew on.

Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

by Zacks Equity Research

Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.

Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

by Zacks Equity Research

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

by Zacks Equity Research

Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.

Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review

by Zacks Equity Research

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

by Zacks Equity Research

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.

Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod

by Zacks Equity Research

Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.

Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds

by Zacks Equity Research

Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.

5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock

by Zacks Equity Research

Here are five aspects that investors may consider while investing in Pfizer's (PFE) stock.

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    by Zacks Equity Research

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

      Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

      by Zacks Equity Research

      Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.

        Indrajit Bandyopadhyay headshot

        Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat

        by Indrajit Bandyopadhyay

        Merck KGaA (MKGAF) reports a mixed second-quarter with earnings declining year-over-year while sales remaining flat.

          What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

          by Zacks Equity Research

          Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.

            Juniper Inks Deal to be Acquired by Catalent, Shares Up

            by Zacks Equity Research

            Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.